Analysts have been eager to weigh in on the Healthcare sector with new ratings on Can-Fite BioPharma (CANF – Research Report), CareDx (CDNA – Research Report) and Evotec AG (EVO – Research Report).
Can-Fite BioPharma (CANF)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Can-Fite BioPharma, with a price target of $34.00. The company’s shares closed last Thursday at $4.05, close to its 52-week low of $3.78.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of
Currently, the analyst consensus on Can-Fite BioPharma is a Moderate Buy with an average price target of $34.00.
See Insiders’ Hot Stocks on TipRanks >>
CareDx (CDNA)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on CareDx. The company’s shares closed last Thursday at $15.20, close to its 52-week low of $10.50.
According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CareDx with a $31.50 average price target.
Evotec AG (EVO)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Evotec AG today and set a price target of $12.00. The company’s shares closed last Thursday at $10.34.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Evotec AG with a $12.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CANF:
